ABU
DHABI, UAE, June 6, 2024
/PRNewswire/ -- At BIO 2024 International Convention, the
Department of Health – Abu Dhabi
(DoH), the regulator of the healthcare sector in the Emirate,
signed a Memorandum of Understanding (MoU) with Novartis Middle
East FZE, a global pharmaceutical company. Under the terms of
the MoU, the entities will work together to advance solutions in
multiple therapeutic areas. The two priority focus areas include
advancing clinical genomics research for real-world evidence (RWE)
and generating and disseminating evidence to support the
understanding of radioligand therapy (RLT) for cancer
patients.
In the presence of Thierry
Diagana, Head of Global Health and California Sites Head at
Novartis Biomedical Research, the MoU was signed by Dr Asma Ibrahim Al Mannaei, the Executive Director
of the Research and Innovation Centre at DoH and Ibrahim Aqel, Head of Government Affairs and
Value & Access – Gulf at Novartis.
This collaboration will utilise Abu
Dhabi's genomics expertise and its future-forward, agile
regulatory framework research hub to collaborate on future clinical
research and the generation of RWE. This will include exploration
of innovative solutions and genomics research in oncology,
cardiovascular disease, and neuroscience. The two will also work
together to generate and disseminate evidence to support the
awareness and understanding of RLT – a form of precision nuclear
medicine that may recognise and treat disease in patients with
advanced cancers – with key stakeholders.
Dr. Asma Ibrahim Al
Mannaei said: "Novartis has been a long-standing
partner to the Department of Health, and we are proud to explore
these new areas of opportunity to collaborate for the ultimate
benefit of patients in the region and beyond. We believe that
this
partnership will allow us to further accelerate the field of
personalised and precision medicine across important therapeutic
areas. As we continue to establish Abu
Dhabi as a hub for global life science and a centre for
innovative research, we are excited to work in synergy with our
strategic partners, and combine our expertise in the pursuit of
common goals."
Novartis and DoH will explore innovative solutions for local and
regional health needs. This will include supporting the Emirati
Genome Programme by collaborating to raise awareness of genetic and
rare diseases. The final focus area is supporting the further
improvement of the Health Technology Assessment through facilitated
partnership and shared best practice.
Mohamed Ezz Eldin Head of Gulf
countries for Novartis, said: "We are thrilled to announce our
collaboration with the Department of Health – Abu Dhabi through the signing of this
Memorandum of Understanding. This partnership represents a
significant milestone in advancing research and innovation in
healthcare, particularly in the fields of oncology, cardiovascular
diseases, and neuroscience. Novartis is committed to supporting the
development of clinical research capabilities in Abu Dhabi, generating real-world evidence, and
raising awareness about radioligand therapy. We look forward to
working closely with the Department of Health – Abu Dhabi to drive innovation and enhance the
Health Technology Assessment capabilities in the region. Our goal
is to contribute to personalized and precision medicine, ultimately
improving patient outcomes"
Led by the Department of Health – Abu
Dhabi (DoH), a high-profile Abu
Dhabi delegation headed by His Excellency Mansoor Ibrahim Al
Mansoori, Chairman of the DoH, is visiting the United States of America (USA) between May
29th,2024 and June
5th,2024 to showcase the Emirate's partnership
opportunities and explore collaboration with leading organizations
in Research and Development (R&D), manufacturing and
innovation. Kicking-off in Philadelphia, delegates have met with existing
and new partners to foster collaboration with leading education
research institutions, governmental bodies and health-tech giants.
The transnational mission has culminated in San Diego, coinciding with Abu Dhabi's participation at BIO International
Convention 2024 to exhibit the Emirate's growth and development of
its biotechnology industry.
The participation has witnessed in-depth discussions, shared
insights and expertise as well as explored collaborations in
health-tech, life science and innovation.
Photo -
https://mma.prnewswire.com/media/2432775/DoH_and_Novartis.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/department-of-health--abu-dhabi-and-novartis-to-partner-to-advance-genomics-research-in-oncology-and-beyond-302166654.html
SOURCE The Department of Health - Abu
Dhabi